NCT07154810Active, not recruiting
Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
Observational Study to Evaluate Long-term Follow-up of Subjects Implanted With Sustained-release Bimatoprost With the SpyGlass IOL in Subjects With Ocular Hypertension or Mild-to-moderate Open-angle Glaucoma
Source: ClinicalTrials.gov · Last updated 4 Sept 2025
Brief summary (registry, in English)
The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma. It will also further observe and learn about the safety of the Bimatoprost Implant System / IOL Combination. The main questions it aims to answer are: * Does the Bimatoprost Implant System / IOL Combination continue lower the pressure inside the eye to treat ocular hypertension or glaucoma long term? * Does the Bimatoprost Implant System / IOL Combination continue to correct vision after cataract surgery long term? * What long term medical problems do participants have when treated with the Bimatoprost Implant System / IOL Combination?
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 23 (actual)
- First submitted
- 22 Aug 2025
- Start date
- 16 Mar 2023
- Primary completion date
- 14 Apr 2031
- Lead sponsor
- SpyGlass Pharma, Inc.
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT07154810
What you commit to
- Study type: Observational
- Participants enrolled: 23
- From 16 Mar 2023 to the primary completion date, 14 Apr 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Planned participation in another clinical trial within 30 days of the initial study visit that, in the investigator's opinion, could confound the study results
Who the study is looking for
- Be able to understand a written informed consent and be willing to participate by evidence of signing an informed consent form
- Met all inclusion criteria, participated in and completed the SGP-SPEC-001 study
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centro Oftalmológico Robles Coordinator of this site? Confirm its status | Santa Rosa de Copán | Honduras | Unknown status |
Related publications
- Prospective Pilot Study of Sustained Release Bimatoprost Implant with SpyGlass Intraocular Lens: 3-Year Results.Ophthalmol Ther · 2026 · PMID 41621045
This page is information, not medical advice. Discuss any trial with your doctor.